Wealth Enhancement Advisory Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.54M	Sell	84,937 -27,438	-24%	-$1.5M	0.01%	1069
2026 Q1	$5.64M	Buy	112,375 +28,572	+34%	+$1.67M	0.01%	847
2025 Q4	$5.05M	Sell	83,803 -5,621	-6%	-$306K	0.01%	1015
2025 Q3	$4.89M	Buy	89,424 +15,043	+20%	+$860K	0.01%	959
2025 Q2	$4.28M	Buy	74,381 +29,797	+67%	+$1.75M	0.01%	966
2025 Q1	$3.15M	Buy	44,584 +21,383	+92%	+$1.44M	0.01%	1026
2024 Q4	$1.53M	Buy	23,201 +17,340	+296%	+$1.16M	﹤0.01%	1314
2024 Q3	$412K	Buy	5,861 +2,289	+64%	+$191K	﹤0.01%	1958
2024 Q2	$294K	Buy	+3,572	New	+$297K	﹤0.01%	1994

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Wealth Enhancement Advisory Services's BMRN Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its BioMarin Pharmaceuticals (BMRN) stake by 24% in Q2 2026, selling an estimated $1.5M and leaving 84,937 shares worth $4.54M. The position accounts for 0.01% of the portfolio, ranked #1069.

Wealth Enhancement Advisory Services first reported a position in BMRN in Q2 2024 and has held it in 9 quarters since. The position peaked at $5.64M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Wealth Enhancement Advisory Services held 84,937 shares of BioMarin Pharmaceuticals worth $4.54M as of Q2 2026.
Wealth Enhancement Advisory Services sold 27,438 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.5M.
BioMarin Pharmaceuticals made up 0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #1069 holding.
Wealth Enhancement Advisory Services first reported a position in BioMarin Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Wealth Enhancement Advisory Services's BioMarin Pharmaceuticals position peaked at $5.64M in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.